<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02623699</url>
  </required_header>
  <id_info>
    <org_study_id>233AS101</org_study_id>
    <secondary_id>2015-004098-33</secondary_id>
    <nct_id>NCT02623699</nct_id>
  </id_info>
  <brief_title>An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)</brief_title>
  <acronym>VALOR (Part C)</acronym>
  <official_title>A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB067 Administered to Adult Subjects With Amyotrophic Lateral Sclerosis and Confirmed Superoxide Dismutase 1 Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of Parts A and B of this study is to evaluate the safety, tolerability,
      and pharmacokinetics (PK) of BIIB067 (Tofersen) in adult with ALS. The primary objective of
      Part C of this study is to evaluate the clinical efficacy of BIIB067 administered to adult
      participants with ALS and confirmed superoxide dismutase 1 (SOD1) mutation.

      The secondary objective of Parts A and B of this study is to evaluate the effects of BIIB067
      on levels of SOD1 protein in the cerebrospinal fluid (CSF). The secondary objectives of Part
      C are to evaluate the safety, tolerability, and pharmacodynamic (PD) effects of BIIB067
      administered to adult participants with ALS and confirmed SOD1 mutation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 3-part study to examine the efficacy, safety, tolerability, PK and PD of BIIB067.
      Part A is the single ascending dose (SAD) component of the study, Part B is the multiple
      ascending dose (MAD) component of the study and Part C is the fixed dose component of the
      study. Hence, the overall phase of development of the study is 1/2/3.

      Parts A and B were completed on 15-Jan-2019. In total, the study is estimated to enroll 183
      participants, with 99 in Part C.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2016</start_date>
  <completion_date type="Anticipated">July 6, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 6, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Part A and B: Up to Day 169</time_frame>
    <description>An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A SAE is any untoward medical occurrence that at any dose results in death, life-threatening event, requires inpatient hospitalization, significant disability/incapacity or congenital anomaly.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Laboratory Assessment Abnormalities</measure>
    <time_frame>Part A and B: Up to Day 169</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Vital Sign Abnormalities</measure>
    <time_frame>Part A and B: Up to Day 169</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Physical Examination Abnormalities</measure>
    <time_frame>Part A and B: Up to Day 169</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Neurological Examination Abnormalities</measure>
    <time_frame>Part A and B: Up to Day 169</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant 12-lead Electrocardiograms (ECGs) Abnormalities</measure>
    <time_frame>Part A and B: Up to Day 169</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter of BIIB067 in Plasma: Maximum Observed Concentration (Cmax)</measure>
    <time_frame>Part A and B: Up to Day 169</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter of BIIB067 in Plasma: Time to Reach Maximum Observed Concentration (Tmax)</measure>
    <time_frame>Part A and B: Up to Day 169</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)</measure>
    <time_frame>Part A and B: Up to Day 169</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast)</measure>
    <time_frame>Part A and B: Up to Day 169</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter of BIIB067 in Plasma: Apparent Terminal Elimination Half-life (t1/2)</measure>
    <time_frame>Part A and B: Up to Day 169</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameters of BIIB067 in CSF Levels: Terminal Elimination Half-life (t1/2)</measure>
    <time_frame>Part A and B: Up to Day 169</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Total Score at Week 28</measure>
    <time_frame>Part C: Baseline to Day 197</time_frame>
    <description>There are 12 questions, each scored from 0 (no function) to 4 (full function). Total possible score is 48. ALSFRS-R scores calculated at diagnosis can be compared to scores throughout time to determine the speed of progression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CSF Levels of SOD1 Protein.</measure>
    <time_frame>Part A, B and C: Up to Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Slow Vital Capacity (SVC)</measure>
    <time_frame>Part C: Baseline to Day 197</time_frame>
    <description>Vital capacity will be measured by means of an SVC test, administered in the upright position.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilation Assistance-free Survival (VAFS)</measure>
    <time_frame>Part C: Baseline to Day 225</time_frame>
    <description>It is defined as the time to the earliest occurrence of one of the following events: death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Part C: Baseline to Day 225</time_frame>
    <description>Overall survival is defined as the time from randomization until death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Muscle Strength Measured by Handheld Dynamometry (HHD)</measure>
    <time_frame>Part C: Baseline to Day 197</time_frame>
    <description>Quantitative muscle strength will be evaluated using HHD, which tests isometric strength of multiple muscles using standard participant positioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Part C: Baseline to Day 225</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Phosphorylated Axonal Neurofilament heavy chain (p-NFH) Concentration in CSF</measure>
    <time_frame>Part C: Baseline to Day 169</time_frame>
    <description>p-NFH is a biomarker whose concentration will be assessed in CSF.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">183</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Single Ascending Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A: Randomized single ascending dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B: Randomized multiple ascending dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fixed Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part C: Fixed Dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIIB067</intervention_name>
    <description>Part A, B and C</description>
    <arm_group_label>Fixed Dose</arm_group_label>
    <arm_group_label>Multiple Ascending Dose</arm_group_label>
    <arm_group_label>Single Ascending Dose</arm_group_label>
    <other_name>Tofersen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Part A, B and C</description>
    <arm_group_label>Fixed Dose</arm_group_label>
    <arm_group_label>Multiple Ascending Dose</arm_group_label>
    <arm_group_label>Single Ascending Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria: Part A and B

          -  Weakness attributable to ALS and documented SOD1 mutation at Screening Visit 2.

          -  A forced vital capacity (FVC) ≥50% of predicted value as adjusted for sex, age, and
             height (from the sitting position). Participants with stable FVC &lt;50% but ≥45%, whose
             FVC has not declined by more than 5% in the last 6 months may be considered for
             inclusion, at the discretion of the Investigator.

          -  If taking riluzole, participant must be on a stable dose for ≥30 days prior to Day 1
             and expected to remain at that dose until the final study visit.

          -  Medically able to undergo the study procedures, and to adhere to the visit schedule at
             the time of study entry, as determined by the Investigator.

        Key Exclusion Criteria: Part A and B

          -  History of or positive test result for human immunodeficiency virus.

          -  History of, or positive test result at Screening, for hepatitis C virus antibody.

          -  Current hepatitis B infection (defined as positive for hepatitis B surface antigen
             [HBsAg] and/or hepatitis B core antibody [HBcAb]). Participants with immunity to
             hepatitis B from previous natural infection (defined as negative HBsAg, positive
             hepatitis B surface antibody immunoglobulin G, and positive HBcAb) or vaccination
             (defined as positive anti-HBs) are eligible to participate in the study.

          -  Treatment with another investigational drug, biological agent, or device within 1
             month or 5 half-lives of study agent, whichever is longer. Specifically, no prior
             treatment with small interfering ribonucleic acid, stem cell therapy, or gene therapy
             is allowed.

          -  Current enrollment in any other interventional study.

          -  Current or recent (within 1 month) use, or anticipated need, in the opinion of the
             Investigator, of copper (II) (diacetyl-bis (N4-methylthiosemicarbazone)) or
             pyrimethamine.

          -  Current or anticipated need, in the opinion of the Investigator, of a diaphragm pacing
             system (DPS) during the study period.

        Key Inclusion Criteria: Part C

          -  Weakness attributable to ALS and confirmed SOD1 mutation at Screening Visit.

          -  If taking riluzole, participant must be on a stable dose for ≥30 days prior to Day 1
             and expected to remain at that dose until the final study visit.

          -  If taking edaravone, participant must have initiated edaravone ≥60 days (2 treatment
             cycles) prior to Day 1 and expected to remain at that dose until the final study
             visit, unless the Investigator determines that edaravone should be discontinued for
             medical reasons, in which case it may not be restarted during the study. Edaravone may
             not be administered on dosing days of this study.

          -  Medically able to undergo the study procedures and to adhere to the visit schedule at
             the time of study entry, as determined by the Investigator.

        Key Exclusion Criteria: Part C

          -  History of or positive test result for human immunodeficiency virus.

          -  Current hepatitis C infection (defined as positive hepatitis C virus [HCV] antibody
             and detectable HCV ribonucleic acid [RNA]). Participants with positive HCV antibody
             and undetectable HCV RNA are eligible to participate in the study (United States
             Centers for Disease Control and Prevention).

          -  Current hepatitis B infection (defined as positive for HBsAg and/or anti-HBc).
             participants with immunity to hepatitis B from previous natural infection (defined as
             negative HBsAg, positive anti-HBc, and positive anti-HBs) or vaccination (defined as
             negative HBsAg, negative anti-HBc, and positive anti-HBs) are eligible to participate
             in the study.

          -  Treatment with another investigational drug (including investigational drugs for ALS
             through compassionate use programs), biological agent, or device within 1 month or 5
             half-lives of study agent, whichever is longer. Specifically, no prior treatment with
             small interfering RNA, stem cell therapy, or gene therapy is allowed.

          -  Current enrollment in any other interventional study.

          -  Current or recent (within 1 month) use, or anticipated need, in the opinion of the
             Investigator, of copper (II) (diacetyl-bis(N4-methylthiosemicarbazone)) or
             pyrimethamine.

          -  Current or anticipated need, in the opinion of the Investigator, of a DPS during the
             study period.

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US Biogen Clinical Trial Center</last_name>
    <phone>866-633-4636</phone>
    <email>clinicaltrials@biogen.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Global Biogen Clinical Trial Center</last_name>
    <email>clinicaltrials@biogen.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aide Raya</last_name>
      <phone>602-406-8144</phone>
      <email>aide.raya@dignityhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California San Diego Medical Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0949</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rose Previte</last_name>
      <phone>858-246-1319</phone>
      <email>rprevite@ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Milan</last_name>
      <phone>415-600-5764</phone>
      <email>milanjr@sutterhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Miami School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Laure Grignon</last_name>
      <phone>305-243-8928</phone>
      <email>axg1571@med.miami.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bioclinica Research</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Bubalo</last_name>
      <phone>407-734-7841</phone>
      <email>matthew.bubalo@globalaes.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Riley</last_name>
      <email>kriley15@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Massachusetts General Hospital</last_name>
      <phone>617-643-2522</phone>
      <email>yafukumura@mgh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Vallis</last_name>
      <phone>313-916-1364</phone>
      <email>avallis1@hfhs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Sultze</last_name>
      <phone>507-538-5523</phone>
      <email>sultze.jane@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesse Markway</last_name>
      <phone>844-257-2273 or 314-362-6159</phone>
      <email>als@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neurology Associates, P.C.</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Calhoun</last_name>
      <phone>402-770-7403</phone>
      <email>ashley@somnos.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ALSresearch@columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Hastings</last_name>
      <phone>216-445-3353</phone>
      <email>hastind@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Providence ALS Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arlena Cummings, CCRP</last_name>
      <phone>503-962-1171</phone>
      <email>arlena.cummings@providence.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Orleans Center for Clinical Research/Volunteer Research Group, an AMR Company</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Smith</last_name>
      <phone>865-305-9100</phone>
      <email>william.smith@amrllc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Methodist Neurological Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Halton</last_name>
      <phone>713-441-3420</phone>
      <email>slhalton@houstonmethodist.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steve Vucic</last_name>
      <phone>+61 2 8890 8738</phone>
      <email>steve.vucic@sydney.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+32 16344280</phone>
      <email>ann.dhondt@uzleuven.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Calgary - Health Sciences Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 1N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lawrence Korngut</last_name>
      <phone>403-210-7009</phone>
      <email>jamarti@ucalgary.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jahan Mookshah</last_name>
      <phone>416-480-6100</phone>
      <phone_ext>x87561</phone_ext>
      <email>jahan.mookshah@sunnybrook.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yousra Khalfallah</last_name>
      <phone>514-398-6188</phone>
      <email>yousra.khalfallah@mcgill.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie H Nielsen</last_name>
      <phone>0045 20876484</phone>
      <email>julie.holm.nielsen.01@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Pitie Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maryvonne Retail</last_name>
      <phone>+33 01 42 16 19 70</phone>
      <email>maryvonne.retail@aphp.fr</email>
    </contact>
    <contact_backup>
      <phone>+33 01 42 16 57 62</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Baden Wuerttemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastian Michels</last_name>
      <phone>+49 (0)731-177 5219</phone>
      <email>sebastian.michels@rku.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ALS Center - Dept. of Neuroscience &quot;Rita Levi Montalcini&quot;, University of Turin</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Fuda</last_name>
      <phone>+39 011 6335439</phone>
      <email>gio.fuda@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Tokyo Hospital</name>
      <address>
        <city>Bunkyo-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kagoshima City</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suita-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sheffield</city>
        <state>South Yorkshire</state>
        <zip>S10 2HQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Sweden</country>
  </removed_countries>
  <link>
    <url>https://www.alsvalorstudy.com/</url>
    <description>Study Website - US Only Sites</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 24, 2015</study_first_submitted>
  <study_first_submitted_qc>December 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2015</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IONIS-SOD1Rx</keyword>
  <keyword>SOD1</keyword>
  <keyword>ALS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on http://clinicalresearch.biogen.com/</ipd_description>
    <ipd_url>http://www.biogenclinicaldatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

